Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data

Nowadays, the biological equipment available for the treatment of moderate-to-severe psoriasis is plenty. Anti-interleukin-23 represents the latest class of biologic approved for the management of moderate-to-severe psoriasis. Their efficacy and safety have been assessed through two major sources: c...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruggiero, Angelo, Megna, Matteo, Fabbrocini, Gabriella, Ocampo-Garza, Sonia Sofia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811885/
https://www.ncbi.nlm.nih.gov/pubmed/36598647
http://dx.doi.org/10.1007/s12026-022-09356-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811885/
https://www.ncbi.nlm.nih.gov/pubmed/36598647
http://dx.doi.org/10.1007/s12026-022-09356-y

Ejemplares similares